– Internet gross sales registered KRW105.1 billion and working revenue achieved KRW53.4 billion, up 23.9% and 54.5% on-year, respectively
– Internet gross sales of toxin rose 41% on-year, because of preliminary cargo to the US
– The abroad gross sales of toxin jumped 73% on-year, backed by strong development in Asia-Pacific
SEOUL, South Korea, Nov. 6, 2024 /PRNewswire/ — Hugel, a number one international medical aesthetics firm, introduced the consolidated monetary assertion for the third quarter of 2024 on November 6, reporting KRW105.1 billion in internet gross sales, KRW53.4 billion in working revenue and KR42 billion in internet earnings.
Backed by the corporate’s international enlargement, the quarterly internet gross sales and working revenue have surpassed KRW100 billion and KRW50 billion for the primary time, respectively, attaining record-high earnings. The online gross sales and revenue respectively elevated 23.9% and 54.5% year-over-year.
By product, gross sales of botulinum toxin “Botulax (name for export: Letybo)” rose 41% on-year to achieve KRW64.7 billion. The toxin’s abroad gross sales jumped 73% within the third quarter on-year, because of the preliminary cargo to the US in July and September and strong development from the Asia-Pacific market. Toxin gross sales in South Korea climbed greater than 5% on-year, pushed by accounts enlargement and optimistic responses for 300 IU within the home market.
Gross sales of hyaluronic acid (HA) fillers THE CHAEUM (title for export: Revolax, Dermalax and Persnica) and BYRYZN SKINBOOSTER HA amounted to KRW29.9 billion within the third quarter. The online gross sales of the fillers in Europe had been up 7% year-over-year, with regular development throughout international markets.
Cosmetics manufacturers reminiscent of WELLAGE and BYRYZN BR posted a 37.4% rise in gross sales year-over-year. Derma cosmetics model WELLAGE launched new lineup Hyper Peptide in August, and high-end cosmetics model BYRYZN BR has been growing its shopper base since its market debut in April. Bioabsorbable suture BlueRose can also be strengthening its development.
Hugel goals to speed up the Korean and abroad market enlargement within the fourth quarter. The corporate plans to formally launch Botulax (title for export: Letybo) later this 12 months within the US market, the corporate’s essential focus, through collaborations with its California-based companion BENEV Firm Inc. Hugel can even actively push gross sales and advertising actions to be well-positioned and obtain round 10% share within the US market inside three years.
“Hugel posted record-high quarterly earnings with the strong performance of botulinum toxin and fillers in global markets, exceeding KRW100 billion in net sales and KRW50 billion in operating profit. In the fourth quarter, we will successfully launch botulinum toxin in the US and make company-wide efforts to strengthen its presence in around 70 countries such as the Asia-Pacific and European markets,” a Hugel official mentioned.
About Hugel
Established in 2001, Hugel is a number one international medical aesthetics firm that manufactures injectables for pores and skin rejuvenation reminiscent of botulinum toxin, hyaluronic acid fillers and pores and skin boosters in addition to absorbable sutures and cosmetics merchandise. The corporate is the one South Korean provider to the world’s three largest botulinum toxin markets, the US, China and Europe. It exports medical aesthetic merchandise and units to round 70 nations and operates eight international subsidiaries within the US, Australia, Canada, Taiwan, China, Hong Kong and Singapore.
Contact:
Jihyun Kim, Supervisor of the PR Group, Hugel
jihyun.kim@hugel-inc.com
